ArticleFrontiers in cell and developmental biology2026
Young cardiac telocyte-derived exosomes rejuvenate aging hearts in rats.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Effective clinical strategies for rejuvenating aging hearts are needed to reverse and cure aging-related pathological cardiac degeneration. The present study was designed to investigate the potential rejuvenating effects of young cardiac telocyte (CT)-derived exosomes (Y-CT-exos) on cardiac aging and aging-related pathological cardiac degeneration. Methods: Y-CT-exos were prepared from young CTs. Twenty-four-month-old female Sprague‒Dawley rats were used as an aged model to evaluate the benefits of Y-CT-exos on cardiac aging and aging-related pathological cardiac degeneration. Nanoparticle tracking analysis, zeta potential measurements, Western blotting, qPCR, β-gal, ROS and PKH26 staining, multiplex immunoassays, Masson's trichrome and immunohistochemical staining, motor function tests, wheat germ agglutinin staining and echocardiography, etc., were performed to evaluate the quality and distribution of the Y-CT-exos and their effects against cardiac aging. RNA sequencing was performed to compare the changes in the transcriptomes between aged hearts and Y-CT-exos-treated aged hearts, and differentially expressed genes (DEGs) were identified. Ingenuity pathway analysis (IPA) was used to identify related genes, their associated pathways, and the up- and downstream interaction networks underlying the rejuvenating effects of Y-CT-exos on cardiac aging and cardiac pathological improvement. Results: Y-CT-exos rejuvenated cardiac aging by ameliorating the senescence of cardiomyocytes and cardiac fibroblasts, the accumulation of DNA and ROS damage in cardiomyocytes, inflammation in the hearts and body of aged rats, promoting the proliferation of cardiomyocytes, improving aging-related decreases in cardiac function, and alleviating cardiomyocyte hypertrophy and cardiac fibrosis. In addition, the related genes, their associated pathways and the up- and downstream interaction networks underlying the therapeutic effects of reversed cellular senescence (inhibition of the p38 MAPK signaling pathway and activation of the antioxidant function of vitamin C), inflammatory aging (inhibition of the inflammasome pathway), and cardiomyocyte hypertrophy, were revealed. Conclusion: Y-CT-exos, the identified genes and their up- and downstream interaction networks, which are involved in the alleviation of cellular senescence, inflammatory aging and cardiomyocyte hypertrophy, have great potential for the development of novel cell-free therapies to rejuvenate aging hearts and ameliorate the aging-related decrease in cardiac function, cardiac hypertrophy and cardiac fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.